Fastpharming Contract Development News Today

BRYAN, Texas and SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation...

BRYAN, Texas, Feb. 14, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and...

07.02.2022 - BRYAN, Texas, Feb. 07, 2022 (GLOBE NEWSWIRE) - iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System, announced today that ...

- Shareholders Continue to Support Reverse Split and Authorized Share Proposals by a 2-to-1 Margin -...

Industry veteran adds deep expertise in immuno-oncology to the Board...

- Industry veteran adds deep expertise in immuno-oncology to the Board - Bryan, Texas / August 26, 2021 / / iBio, Inc. , a developer of next-generation biopharmaceuticals and... | August 29, 2021

[December 28, 2020] iBio Appoints Dr. Martin B. Brenner as Chief Scientific Officer BRYAN, Texas, Dec. 28, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Martin B. Brenner, DVM, Ph.D., as its Chief Scientific Officer (“CSO”), effective January 18, 2020. “We are thrilled to have Dr. Brenner join our team,” said Tom Isett, C...